Cencora (COR) Could Be 15% Undervalued As Earnings Date Nears
Cencora (COR) is approaching its fiscal third-quarter earnings release on August 5, 2026, with current analysis suggesting it might be undervalued by 15.4%. The company's stock has shown strong long-term performance, and its investments in digital infrastructure are expected to drive higher margins and operating income. However, potential risks include increased regulatory scrutiny on drug pricing and heightened competition in specialty distribution.
Jim Cramer on Cardinal Health: “It’s Been a Real Stalwart, and I Don’t Think It’s Done”
Jim Cramer expressed confidence in Cardinal Health (NYSE: CAH), recommending it to investors and stating that the stock deserves to trade higher despite a recent rotation out of healthcare. He highlighted the company's strong performance in a recent quarter. Cardinal Health supplies branded and generic medicines, and medical products.
Jim Cramer on Cardinal Health: “It’s Been a Real Stalwart, and I Don’t Think It’s Done”
Jim Cramer highlighted Cardinal Health (NYSE: CAH) as a strong stock that deserves to trade higher, despite being obscured by a recent healthcare sector rotation. He emphasized the company's "great quarter" and its position as a "real stalwart." Cramer also mentioned an earlier implosion of the stock that concerned him, but still believes in its potential going forward.
Jim Cramer on Cardinal Health: “It’s Been a Real Stalwart, and I Don’t Think It’s Done”
Jim Cramer expressed confidence in Cardinal Health (NYSE: CAH), recommending it among healthcare stocks that deserve to trade higher. He highlighted its strong performance, despite a recent market rotation out of healthcare, and noted that it is held in his Trust. Cramer believes the stock is a "stalwart" and has further upside potential.
Is Cardinal Health (CAH) Fully Valued After Its Russell Index Removal?
Cardinal Health (CAH) has been removed from several Russell indices, prompting investors to re-evaluate the stock. Despite a strong share price performance and analysts' valuation indicating it's slightly undervalued, its P/E ratio suggests a higher valuation risk compared to the industry and peers. The article discusses whether its current price reflects demanding future expectations.
Is Cardinal Health (CAH) Fully Valued After Its Russell Index Removal?
Cardinal Health (CAH) was removed from several Russell indices following strong share price performance, leading investors to re-evaluate the stock. While Simply Wall St's narrative suggests it's slightly undervalued at $245.27, its P/E ratio of 36x is higher than the industry average, signaling potential valuation risk. Investors are encouraged to assess the full picture of the company's rewards and risks.
McKesson stock trades steadily as healthcare distribution remains a pillar for US providers
McKesson stock is trading steadily due to the company's crucial role as a major US healthcare distributor. Its business focuses on pharmaceutical and medical supply distribution, essential for the US healthcare system. The company's stability is driven by consistent demand for healthcare, long-term contracts, and technological advancements in logistics.
MCK - Mckesson Corp Latest SEC Filings
This article provides the latest SEC filings and comprehensive financial data for McKesson Corp (MCK). It includes current stock performance metrics, valuation ratios, dividend information, and insider and institutional ownership percentages, alongside various profitability and efficiency ratios.
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
McKesson (MCK) is recommended for retention due to robust growth in specialty distribution, oncology services, and biopharma solutions, along with improving earnings and strong specialty pharmaceutical momentum. The company faces potential headwinds from IRA-driven drug pricing pressure, uncertain technology solutions growth, and risks associated with its acquisition-led strategy. Despite these challenges, positive estimate revisions for 2026 and a Zacks Rank #3 (Hold) suggest continued stability.
Is McKesson (MCK) Undervalued On Softer Results And New Partnerships?
McKesson (MCK) has experienced mixed share price performance recently, with a 2.09% decline but a 4.52% one-month gain, amidst softer quarterly results and its inclusion in Russell 1000 defensive indexes. The company is considered undervalued by a widely followed narrative, trading at $768.06 against a fair value of $941.40, driven by increased adoption of specialty pharmaceuticals and strategic acquisitions positioning it for higher operating margins. While an earnings-based view suggests a significant valuation gap, potential risks such as regulatory pressure on drug pricing or vertical integration in the pharmaceutical supply chain could impact its future.
McKesson Corp. stock outperforms competitors on strong trading day
McKesson Corp. (MCK) shares increased by 2.37% to $786.30 on Thursday, outperforming the S&P 500 Index and the Dow Jones Industrial Average. This marks the third consecutive day of gains for the stock. The broader market experienced a mixed trading session, with the S&P 500 largely unchanged and the Dow Jones showing a gain.
McKesson Corporation highlights its role in U.S. healthcare distribution as investors watch long-ter
McKesson Corporation is a major player in the U.S. healthcare distribution and services sector, critical for supplying medicines and medical products. Its role is shaped by aging demographics, and its stable revenue streams are supported by its extensive logistics, technology investments, and contractual arrangements. Investors evaluate McKesson based on its ability to manage costs, adapt to regulatory changes, and leverage technology within the complex healthcare landscape.
McKesson (MCK) Spotlights AI-Powered Tools for Independent Pharmacies at Its Annual ideaShare Conference
McKesson (NYSE: MCK) showcased AI-powered solutions for independent pharmacies at its annual ideaShare 2026 conference, focusing on integrating AI into pharmacy operations, expanding patient care services, and community-based care. The event, which gathered nearly 5,000 pharmacy professionals, also featured a Product Showcase for attendees to evaluate and vote on new tools. This comes after Apollo acquired a 13% minority stake in McKesson’s Medical-Surgical Solutions business in a $1.25 billion deal.
McKesson (MCK) Spotlights AI-Powered Tools for Independent Pharmacies at Its Annual ideaShare Conference
McKesson (MCK) recently highlighted its AI-powered solutions for independent pharmacies at its annual ideaShare 2026 conference, which brought together nearly 5,000 pharmacy professionals. The event focused on integrating AI into pharmacy operations, expanding patient care services, and emphasizing community-based care. Additionally, McKesson closed a strategic investment deal where Apollo acquired a minority stake in McKesson's Medical-Surgical Solutions business for $1.25 billion.
McKesson exec to retire in another C-suite change for pharma giant
McKesson, the Irving-based drug distribution giant, announced the retirement of Thomas Rodgers, its chief strategy and business development officer, roughly a month after the company welcomed a new CFO. This marks another significant change in the C-suite for DFW's largest locally headquartered public company.
McKesson Corporation Announces Management Changes, Effective August 1, 2026
McKesson Corporation announced that its Executive Vice President, Chief Strategy and Business Development Officer, Thomas L. Rodgers, will retire on August 1, 2026. Ramesh Srinivasan has been appointed as Executive Vice President, Chief Strategy Officer, effective the same date, to ensure a smooth transition. This change follows Rodgers' notice of intent to retire on June 29, 2026.
McKesson (NYSE: MCK) EVP Rodgers to retire, Srinivasan to lead strategy
McKesson Corporation announced that Executive Vice President and Chief Strategy and Business Development Officer Thomas L. Rodgers will retire on August 1, 2026. Ramesh Srinivasan will succeed him as Executive Vice President, Chief Strategy Officer, effective the same day, ensuring a smooth leadership transition. This change was reported in an 8-K filing on June 29, 2026, and is described as a planned retirement with a designated successor to maintain continuity in the company's strategy leadership.
Cencora CubixxCT from Cencora Inc. - cold-chain automation for hospital pharmacies
Cencora has introduced CubixxCT, an RFID-enabled, temperature-controlled inventory management system for hospital and specialty pharmacy cold chains in the US. This system automates the tracking of high-value biologic drugs and vaccines, improving compliance, reducing waste, and integrating into existing clinical workflows. It represents Cencora's strategic move into service-based revenue beyond commodity drug wholesaling.
How McKesson’s New Defensive Index Roles and TempraMed Expansion Will Impact McKesson (MCK) Investors
McKesson Corporation (MCK) was recently added to several Russell defensive indexes and expanded its distribution agreement with TempraMed, a move expected to solidify its position as a core defensive healthcare distributor. These developments reinforce McKesson's strategic focus on complex cold chain and specialized medication handling, which aligns with its existing growth catalysts in specialty and oncology services. Investors should consider these strategic advancements alongside potential risks such as regulatory scrutiny on drug pricing that could impact future margins.
How McKesson’s New Defensive Index Roles and TempraMed Expansion Will Impact McKesson (MCK) Investors
McKesson Corporation was recently added to several Russell defensive indexes and expanded its distribution agreement with TempraMed for temperature-controlled medication solutions. These moves solidify McKesson's position as a defensive healthcare distributor and enhance its capabilities in specialized medication handling. While the updates reinforce McKesson's focus on complex pharmaceuticals, investors should also consider potential risks from drug pricing regulation affecting margins.
McKesson Corp. stock outperforms competitors on strong trading day
McKesson Corp. (MCK) saw its stock rally by 1.08% to $755.60 on Tuesday, outperforming the broader market. This strong performance ended a three-day losing streak for the company, even as the S&P 500 and Dow Jones Industrial Average also posted gains.
Biodexa Announces Pricing of $3.5 Million Registered Direct
Biodexa Pharmaceuticals PLC has announced the pricing of a $3.5 million financing through a registered direct offering, a concurrent private placement, and a warrant inducement. The proceeds are intended to fund the company's development programs, working capital, and general corporate purposes. The offering includes American depositary shares (ADSs) and various series of warrants, with closing expected around July 1, 2026, subject to customary conditions and shareholder approval for warrant-related matters.
Cardinal Health opens the week with analyst focus, shares in S&P 500 healthcare
Cardinal Health is starting the week with significant attention from analysts due to its role as a major U.S. healthcare distributor and its inclusion in the S&P 500. Analysts are particularly focused on its operating margin trends, cash generation, and capital returns, balancing pressures from generic drug prices with opportunities in specialty pharmaceuticals. The company's performance and consensus estimates are closely watched by investors, especially concerning its impact on ETF flows and index-tracking strategies.
TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels
TempraMed Technologies Ltd. has announced an expanded strategic partnership with McKesson Medical-Surgical, aiming to boost its North American growth and distribution. This agreement will facilitate the full portfolio distribution of TempraMed's temperature-controlled medication solutions across McKesson's extensive B2B network, including various healthcare providers and platforms. The collaboration is expected to enhance product visibility, streamline procurement for healthcare professionals, and support TempraMed's transition to a more diversified revenue model.
TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels
TempraMed Technologies has announced an expanded strategic partnership with McKesson Medical-Surgical to boost its North American growth and B2B distribution. This agreement will see TempraMed's full product portfolio, including its temperature-controlled medication solutions like VIVI Cap and VIVI Epi, integrated into McKesson's extensive sales and distribution network. The collaboration aims to enhance product visibility, streamline procurement for healthcare providers, and support TempraMed's diversified revenue model.
Is McKesson Corporation (MCK) A Good Stock To Buy Now?
This article summarizes a bullish thesis on McKesson Corporation (MCK), arguing that its recent stock decline presents an attractive buying opportunity. The thesis highlights McKesson's dominant position in pharmaceutical distribution, its asset-light business model generating significant cash flow, and its strategic shift towards higher-margin businesses. Despite a recent revenue miss, the company's core investment thesis remains intact, with conservative estimates suggesting 18% upside and more realistic scenarios pointing to 70% upside.
McKesson Corp. stock underperforms Monday when compared to competitors
McKesson Corp. (MCK) saw its stock price drop by 2.09% on Monday, closing at $747.53, despite an overall positive trading day for the broader market. This marks the third consecutive day of losses for the company's shares. The S&P 500 Index and Dow Jones Industrial Average both saw gains on the same day.
Cardinal Health opens the week with strong momentum, shares extend sector outperformance
Cardinal Health (US14149Y1082) started the week with strong performance, showing a significant one-month gain compared to the broader medical sector and the S&P 500. The prescription drug distributor's shares closed at $237.92, up 1.35% for the day and 17.46% over the last month. This outperformance highlights investor expectations for stable cash flows from long-term supply contracts.
3 Reasons We Love McKesson (MCK)
This article highlights three key reasons to be optimistic about McKesson (MCK), despite its recent stock underperformance. The company demonstrates strong long-term revenue growth and outstanding EPS growth, indicating increasing profitability. Its significant scale in the healthcare distribution sector provides valuable negotiating leverage and contributes to its overall business quality.
McKesson outlines specialty growth strategy, shares anchored in S&P 500 healthcare
McKesson, a major US pharmaceutical distributor and S&P 500 healthcare member, is emphasizing higher-margin specialty and oncology distribution services as a key growth driver. The company's stock shows solid performance, with analysts suggesting it is undervalued, supported by recurring distribution cash flows. Quantitative forecasts project short-term target levels in the high $770s for early July 2026.
Henry Schein focuses on long-term strategy, shares in a defensive health peer group
Henry Schein maintains its position as a mid-cap leader in U.S. healthcare distribution, aligning with defensive healthcare peers due to its long-term strategy. The company focuses on dental, medical, and animal health products for small to mid-sized practitioners, generating over $10 billion in annual revenue. This strategy provides stability and consistent cash flow, distinguishing it from hospital-focused wholesalers while attracting institutional investors seeking defensive sector holdings.
Enterprise value to revenue forward of McKesson Corporation – NYSE:MCK
The article focuses on the enterprise value to revenue forward ratio for McKesson Corporation (NYSE: MCK). It provides an overview of the company's financial data, but the core financial metrics themselves, such as the actual enterprise value to revenue forward, are not present in the provided content. The content is primarily a structure for displaying financial information on TradingView.
States seek to lower drug prices by targeting the companies that manage them for health plans
States across the U.S. are increasingly targeting pharmacy benefit managers (PBMs) to lower prescription drug costs amid consumer concerns about affordability. Legislators in multiple states have passed laws to limit PBM compensation, set minimum pharmacist payments, and increase disclosure requirements, with some measures facing legal challenges from PBMs like CVS Health. While PBMs claim they help reduce drug costs, critics argue they contribute to high prices and squeeze independent pharmacies, leading to a complex debate with federal regulatory efforts also underway.
States seek to lower drug prices by targeting the companies that manage them for health plans
States are increasingly attempting to regulate pharmacy benefit managers (PBMs) to lower prescription drug costs for consumers. Several states passed laws this year to limit PBM compensation, set minimum payments to pharmacists, and demand more transparency, with CVS Health Corp. actively fighting these new regulations. The debate highlights the tension between large PBMs, independent pharmacies, and worried consumers concerned about medication accessibility and affordability.
States seek to lower drug prices by targeting the companies that manage them for health plans
States are taking action to lower drug prices by regulating pharmacy benefit managers (PBMs), which oversee prescription coverage for health insurers. Legislation passed in at least a dozen states aims to limit PBM compensation, establish minimum payments for pharmacists, and increase transparency. This movement is a response to consumer concerns about medication affordability, with some PBMs, like CVS, actively fighting these new regulations through lawsuits and advertising campaigns.
Cardinal Health (CAH) Is Up 7.3% After EPS Beat And Neonatal Respiratory Tailwind News - What's Changed
Cardinal Health (CAH) saw its stock rise by 7.3% after reporting an EPS beat and benefiting from positive news regarding the expanding neonatal intensive care respiratory devices market, projected to reach US$5.70 billion by 2035. This performance reinforces investor confidence in Cardinal Health's healthcare distribution and products platform, despite long-term concerns about margin pressure from regulation and competition. The company's continued share repurchases and focus on growth areas are key aspects of its investment narrative.
McKesson Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.25 Sh
The article provides a financial overview and access to actuals and estimates for McKesson Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.25 Sh (M1CK34) trading on B3, Brazil's stock exchange. It highlights where users can explore reported financial data and analyst estimates, across various financial statements and valuation metrics. The content also includes a disclaimer stating that it is not investment advice.
Enterprise value to revenue forward of McKesson Corporation – SWB:MCK
The article provides financial information for McKesson Corporation (SWB:MCK) on TradingView. It specifically highlights the enterprise value to revenue forward metric for the company. The page is part of a larger financial data platform, offering various tools and data related to stocks, ETFs, and other assets.
Experts at McKesson ideaShare Discuss the Importance of the Meeting
The article highlights the significance of the McKesson ideaShare meeting, where experts convened to discuss pressing issues relevant to the pharmacy sector. This event serves as a crucial platform for professionals to exchange ideas and insights, contributing to advancements in pharmaceutical practices and patient care.
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?
This article compares AbbVie and Pfizer as investment options for 2026, focusing on their post-pandemic growth strategies, drug pipelines, and financial health. While both pharma giants face patent expirations and debt, AbbVie is highlighted for its near-term success with new immunology products and acquisitions, giving it an edge over Pfizer which relies more on potential future approvals and GLP-1 developments. The analysis includes financial metrics, risk profiles, and valuation metrics, concluding that AbbVie is the better buy for 2026.
Health-tech giant McKesson to build $179M distribution hub in Moore
McKesson, a health-tech giant, is investing $179 million to build a new 330,000-square-foot distribution hub in Moore, Oklahoma. This facility will centralize Midwest operations, utilizing advanced automation, robotics, and cold-chain technology to enhance the healthcare supply chain's efficiency and resilience. The project is expected to create over 600 jobs by 2029 and generate an annual GDP contribution of $118 million.
McKesson to Open Regional DC in Oklahoma
Pharmaceutical products distributor McKesson will open a new 330,000-square-foot regional distribution center in Moore, Oklahoma. This facility, representing a $179 million capital investment, will replace an existing center, expand capacity, add cold chain capabilities, and support customers across Oklahoma, Texas, and nearby markets. The project is expected to create over 200 direct jobs and 633 total jobs by its first full year of operations in 2029.
Price to earnings forward of McKesson Corporation – NYSE:MCK
The article focuses on the "Price to earnings forward" metric for McKesson Corporation (NYSE: MCK). It appears to be a financial data point from TradingView, indicating that the market for MCK was closed at the time the data was presented.
McKesson Building $179M OKC Distribution Center
McKesson Corporation, a Fortune 100 company, has chosen Moore, Oklahoma, as the site for a new $179 million automated regional distribution facility at the North Moore Industrial Park. This 330,000-square-foot facility will replace an existing center, enhancing capacity and modernizing capabilities to meet future demand for pharmaceutical distribution in North America. Kadean Construction will be the builder, with completion expected in 2028.
McKesson to build $179 million automated DC in Oklahoma
McKesson Corp. is investing $179 million to build a new, highly automated 330,000-square-foot regional distribution center in Moore, Oklahoma. This facility will replace an existing one, enhancing capacity and modernizing capabilities for pharmaceutical distribution, including state-of-the-art automation and expanded cold chain capacity. The investment aims to improve service to Oklahoma, Texas, and the surrounding region, addressing the increasing complexity of the healthcare supply chain.
What Cardinal Health (CAH) Guidance Raise Means For Valuation
Cardinal Health (CAH) recently reported strong fiscal third-quarter earnings and raised its outlook, driven by its focus on specialty pharmaceuticals. While the company's shares have shown significant momentum and are trading at an intrinsic discount, its current P/E ratio suggests investors may be paying a premium. This article explores the valuation implications, presenting both an "undervalued" narrative and a word of caution based on earnings multiples.
Health care giant McKesson selects Moore for new facility
McKesson Corporation has chosen Moore, Oklahoma, as the location for its new 330,000-square-foot pharmaceutical hub. This significant investment of $179 million is expected to create over 200 new jobs in the area. The facility will serve as a key distribution center for the health care giant.
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
McKesson Corporation (MCK) has been trending on Zacks.com, prompting a look into factors influencing its stock performance. The company's earnings estimates show expected growth for the current and next fiscal years, with a Zacks Rank #3 (Hold) rating. Valuation analysis suggests MCK is trading at a discount compared to its peers.
Cencora (COR) Launches Nucleus Pilot And Names A New HR Chief
Cencora (COR) has announced the pilot launch of its enhanced Nucleus inventory management solution for specialty physician practices and a new Chief Human Resources Officer. These operational and leadership changes are drawing investor attention, especially given the stock's recent performance. The Nucleus pilot aims to refine inventory and data management, while the new CHRO will focus on talent and organizational priorities.
McKesson Corporation Announces First Quarter Fiscal 2027 Earnings Release Date
McKesson Corporation announced that it will release its first quarter fiscal 2027 financial results on Wednesday, August 5, 2026, after market close. The company will also host a live webcast of an earnings conference call for investors at 4:30 PM Eastern Time to discuss the results. The webcast will be accessible on McKesson’s Investor Relations website.
